2024-11-18 - Analysis Report
## Pfizer Inc. (PFE) Stock Report

**1. Performance Comparison and Divergence:**

Pfizer Inc. (PFE) is a biopharmaceutical company that discovers, develops, manufactures, and markets drugs and vaccines.  The provided data shows that PFE has significantly underperformed the S&P 500 (VOO) over the analyzed period.  While VOO had a cumulative return of 123.86%, PFE experienced a cumulative loss of -9.76%. This represents a substantial divergence of -133.62%, placing it at the 0th percentile of the historical range of its relative performance against the S&P 500.


**2. Recent Price Movement:**

* **Closing Price:** $24.8
* **5-Day Moving Average:** $25.99
* **20-Day Moving Average:** $27.36
* **60-Day Moving Average:** $28.25

The stock price is currently trading below all three moving averages, indicating a bearish trend.


**3. Technical Indicators and Expected Return:**

* **RSI (16.78):** This extremely low RSI suggests the stock is oversold.  However, it's crucial to remember that oversold conditions can persist.
* **PPO (-0.84):** A negative PPO indicates bearish momentum.
* **20-Day Relative Divergence (-0.27):**  Shows a recent short-term downward trend.
* **Expected Return (0.0%):**  The provided expected return of 0% implies no anticipated outperformance relative to the S&P 500 over the long term (2+ years).  This should be viewed cautiously, as long-term projections are inherently uncertain. The current price of $24.8, being below all moving averages, doesn't reflect a sharp recent upward or downward movement, though the negative indicators suggest a downtrend.


**4. Recent Earnings and Outlook:**

| Date       | EPS     | Expected EPS | Difference |
|------------|---------|---------------|-------------|
| 2024-10-29 | 1.06    | 0.614         | 0.446       |
| 2024-07-30 | 0.60    | 0.458         | 0.142       |
| 2024-05-01 | 0.82    | 0.516         | 0.304       |
| 2024-01-30 | 0.10    | -0.19         | 0.29        |
| 2023-10-31 | -0.17   | -0.32         | 0.15        |

The most recent earnings (October 29, 2024) significantly beat expectations. However,  the overall trend shows variability and a recent period of lower performance.  Further analysis of the drivers behind these earnings is necessary to assess the long-term outlook.


**5. Financial Information:**

* **Revenue and Profitability:** Shows strong revenue growth, but profit margins have fluctuated significantly, particularly a sharp drop in the last two quarters of 2023.  This suggests potential challenges in maintaining profitability.

* **Capital and Profitability:** ROE has been volatile, indicating fluctuating profitability and efficiency in utilizing shareholder equity. The negative ROE in late 2023 is a serious concern.


**6. News and Recent Issues:**  (This section requires real-time data gathering from sources like Shacknews and Finbold.  I cannot access live news feeds.)  This section should include any recent earnings announcements, analyst ratings changes, and significant market events affecting PFE.  Pay close attention to any commentary about the impact of the post-pandemic market adjustments on PFE's revenue streams (i.e. the waning demand for COVID-related products).


**7. Overall Analysis:**

PFE is currently exhibiting signs of underperformance against the broader market.  Technical indicators suggest an oversold condition but also a bearish trend. While the most recent earnings beat expectations, the overall financial picture displays volatility, particularly in profitability and return on equity.  The significant divergence from the S&P 500 underscores the need for cautious consideration.  A thorough analysis of the news and recent market sentiment is crucial before making any investment decision. The long-term outlook depends heavily on the success of Pfizer's diversification strategy away from Covid-related products and its ability to maintain and grow its revenue streams.


**8. Recommendations:** (This section requires more detailed analysis of the news and market outlook, and is therefore left blank here).  Consider a thorough risk assessment given the current market conditions and the volatility in PFE's financial performance.  Consult with a financial advisor before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investment decisions should be based on thorough research and consideration of your individual risk tolerance.
